Boehringer settles Pradaxa suits

Share this article:

Boehringer Ingelheim is settling around 4,000 Pradaxa lawsuits for $650 million. The company announced Wednesday that it had reached a “comprehensive settlement of state and federal cases” and that the decision “enables Boehringer Ingelheim to focus solely on its mission of improving patients' lives.”

Bloomberg reports this breaks down to around $162,500 per suit and that the agreement comes just months before the first of several lawsuits were expected to begin in September.

The lawsuits center around claims that there was no antidote to prevent bleeding-related deaths among those who took the blood thinner.

BI announced earlier this month that it was going to start testing the antidote idarucizumab among Pradaxa patients.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters